COMMUNIQUÉS West-GlobeNewswire

Vivani Medical CEO Adam Mendelsohn to Present at the Jefferies Global Healthcare Conference on June 4, 2026
28/05/2026
ALAMEDA, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. ( NASDAQ: VANI ) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, [...]
Prime Medicine to Present at Jefferies Global Healthcare Conference
28/05/2026
CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced [...]
Vor Bio to Participate in the 2026 Jefferies Global Healthcare Conference
28/05/2026
BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will provide a corporate update in a [...]
Sapu Nano Unveils Progress in Deciparticle™ Nanomedicine Platform and AI-Driven Oncology Development at BIO 2026
28/05/2026
SAN DIEGO, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- via IBN -- Sapu Nano and Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) today announced that Vuong Trieu, Chief Executive Officer, will present the [...]
Jushi Holdings Inc. Announces Applications Submitted for DEA Registration of State-Licensed Medical Cannabis Operations
28/05/2026
BOCA RATON, Fla., May 28, 2026 (GLOBE NEWSWIRE) -- Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH ) (OTCQX: JUSHF ) , a vertically integrated, multi-state cannabis operator, today announced that it has [...]
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June
28/05/2026
NAARDEN, the Netherlands and MIAMI, May 28, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, [...]
Biomerica Lands a $1.75 Million CDMO Master Services Agreement for IVD Diagnostic Development
28/05/2026
Auto-renewing Master Services Agreement engages Biomerica’s integrated development and manufacturing platform, reflecting the Company’s CDMO strategy as a capital-efficient, parallel revenue stream alongside its core [...]
Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference in New York
28/05/2026
BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody [...]
BioXcel Therapeutics Presents New Data from SERENITY At-Home Phase 3 Trial for Agitation Associated with Bipolar Disorders or Schizophrenia at 2026 ASCP Annual Meeting
28/05/2026
NEW HAVEN, Conn., May 28, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience, [...]
InnoCare Announces the Acceptance of New Drug Application for Orelabrutinib in Primary Immune Thrombocytopenia in China
28/05/2026
BEIJING, May 28, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Center for [...]
Relmada Therapeutics to Present at the Jefferies Global Healthcare Conference
28/05/2026
CORAL GABLES, Fla., May 28, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central [...]
TREOS Bio Appoints Sunjeet Sawhney as Chief Executive Officer
28/05/2026
Former Rappta Therapeutics CEO and Ipsen Global Oncology Franchise Head joins as TREOS advances its off-the-shelf, biomarker-guided cancer immunotherapy platform and prepares for the next stage of clinical development [...]
Felix Offers Ozempic at Generic-Level Pricing as Lower-Cost GLP-1 Demand Remains Elevated Across Canada
28/05/2026
Eligible patients can access Ozempic savings through Felix, alongside continued access to Apo-Semaglutide Felix launches Get Started for Free, waiving the initial $99 clinician visit fee at launch; patients pay $149/ [...]
Anaveon Reports Clinical Benefit of ANV600 in the EXPAND-1 Phase 1 Clinical Trial at ASCO 2026 and Actively Seeks Partners for its Legacy Oncology Portfolio
28/05/2026
BASEL, Switzerland, May 28, 2026 (GLOBE NEWSWIRE) -- Anaveon, a late-stage preclinical biotechnology company focused on reprogramming the immune system for the treatment of autoimmune and inflammatory diseases, today [...]
Zenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD
28/05/2026
- BLA submission based on positive results from Phase 3 INDIGO trial - WALTHAM, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma” or the “Company”) (Nasdaq: ZBIO), a clinical- [...]
NRx Pharmaceuticals (Nasdaq: NRXP) Strategic Partner Emobot Presents Late-Breaking Clinical Validation of the EMOCARE Depression Thermometer at ASCP 2026
28/05/2026
EMOCARE is a smartphone-based passive monitoring tool that generates a continuous, real-time measure of depression from patient voice, facial expression, motion, and screen behavior, and is the first passive monitoring [...]
RadNet to Host Men's Health Webinar on June 13, 2026
28/05/2026
Free public event during National Men’s Health Month features leading physicians addressing coronary artery disease, prostate cancer and lung cancer LOS ANGELES, May 28, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: [...]
Trogenix doses first patient in Phase I/II clinical trial of TGX-007 gene therapy for glioblastoma
28/05/2026
UK and US trial sites open; first patient dosed with TGX-007, Trogenix’s proprietary dual-payload AAV gene therapy TGX-007 leverages Trogenix’s precision synthetic super-enhancer platform that selectively activates [...]
BPGbio to Present Ongoing Phase 2 Study Trial-in-Progress Update of BPM31510 in Newly Diagnosed Glioblastoma at ASCO 2026
28/05/2026
BPM31510 is a first-in-class therapeutic targeting tumor metabolism to re-program mitochondrial microenvironment in Warburg-avid tumors Both safety profile and efficacy data to be highlighted in methylated and [...]

Pages